Bassler Bonnie L — SEC insider filings
SEC reporting owner CIK 1683607. 67 insider filings on record with FilingPulse; latest filed 2026-09-30.
Transaction summary — filings shown
Covers the 50 most recent of 67 filings on record, filed 2022-04-01 to 2026-09-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 19 legs across 17 filings — 17,064 shares, $14,541,745 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 83.
- Largest priced transaction: sale of 1,500 shares @ $800.00 ($1,200,000) in REGENERON PHARMACEUTICALS, INC., filed 2026-01-08.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC. (REGN) | Director | 20 | — | 19 legs · 17,064 sh · $14,541,745 | 46 |
| Royalty Pharma plc (RPRX) | Director | 24 | — | — | 24 |
| Cidara Therapeutics, Inc. (CDTX) | Director | 6 | — | — | 13 |
Insider filings — Bassler Bonnie L
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-30 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 642 @ $58.41 | EDGAR |
| 2026-06-30 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 689 @ $54.40 | EDGAR |
| 2026-06-08 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 4,545 @ $0 | EDGAR |
| 2026-03-31 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 815 @ $45.98 | EDGAR |
| 2026-01-08 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 1,500 @ $374.12 · Sale (S): 1,500 @ $800 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Cidara Therapeutics, Inc. (CDTX) | Disposition to issuer (D): 15 @ $221.50 · Disposition to issuer (D): 1,750 (derivative) · Disposition to issuer (D): 875 (derivative) · Disposition to issuer (D): 1,400 (derivative) · Disposition to issuer (D): 2,125 (derivative) · Disposition to issuer (D): 2,125 (derivative) · +2 more | EDGAR |
| 2026-01-06 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 967 @ $38.74 | EDGAR |
| 2025-11-24 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 760 @ $371.40 · Sale (S): 760 @ $750 · Option exercise (M): 760 (derivative) @ $0 | EDGAR |
| 2025-09-30 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,047 @ $35.79 | EDGAR |
| 2025-06-30 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,064 @ $35.24 | EDGAR |
| 2025-06-18 | 4 | Cidara Therapeutics, Inc. (CDTX) | Grant/award (A): 11,100 (derivative) @ $0 | EDGAR |
| 2025-05-14 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 7,614 @ $0 | EDGAR |
| 2025-04-01 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,141 @ $32.87 | EDGAR |
| 2025-01-06 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/award (A): 166 @ $0 · Grant/award (A): 1,958 (derivative) @ $0 | EDGAR |
| 2025-01-02 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,503 @ $24.94 | EDGAR |
| 2024-12-19 | 4 | Cidara Therapeutics, Inc. (CDTX) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-09-30 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,342 @ $27.92 | EDGAR |
| 2024-08-19 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 756 @ $371.40 · Sale (S): 756 @ $1,170 · Option exercise (M): 756 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 756 @ $371.40 · Sale (S): 756 @ $1,115 · Option exercise (M): 756 (derivative) @ $0 | EDGAR |
| 2024-07-19 | 4 | Cidara Therapeutics, Inc. (CDTX) | Grant/award (A): 2,125 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,399 @ $26.80 | EDGAR |
| 2024-06-25 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 756 @ $371.40 · Sale (S): 756 @ $1,062 · Option exercise (M): 756 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 9,293 @ $0 | EDGAR |
| 2024-06-07 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 827 @ $380.95 · Sale (S): 827 @ $1,011 · Option exercise (M): 827 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,240 @ $30.23 | EDGAR |
| 2024-02-26 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 854 @ $391.92 · Sale (S): 854 @ $979.25 · Option exercise (M): 854 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 827 @ $380.95 · Sale (S): 827 @ $959 · Option exercise (M): 827 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/award (A): 135 @ $0 · Option exercise (M): 826 @ $380.95 · Sale (S): 826 @ $914 · Option exercise (M): 826 (derivative) @ $0 · Grant/award (A): 1,607 (derivative) @ $0 | EDGAR |
| 2023-12-29 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,353 @ $27.71 | EDGAR |
| 2023-12-14 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 610 @ $376.69 · Sale (S): 610 @ $870 · Option exercise (M): 610 (derivative) @ $0 | EDGAR |
| 2023-10-03 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,384 @ $27.08 | EDGAR |
| 2023-08-23 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 853 @ $391.92 · Sale (S): 853 @ $829 · Option exercise (M): 853 (derivative) @ $0 | EDGAR |
| 2023-08-11 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 853 @ $391.92 · Sale (S): 853 @ $789 · Option exercise (M): 853 (derivative) @ $0 | EDGAR |
| 2023-06-30 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,208 @ $31.03 | EDGAR |
| 2023-06-26 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 7,747 @ $0 | EDGAR |
| 2023-06-23 | 4 | Cidara Therapeutics, Inc. (CDTX) | Grant/award (A): 42,500 (derivative) @ $0 | EDGAR |
| 2023-03-31 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,049 @ $35.73 | EDGAR |
| 2023-03-27 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 1,240 @ $380.95 · Sale (S): 1,240 @ $818 · Option exercise (M): 1,240 (derivative) @ $0 | EDGAR |
| 2023-02-07 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 1,021 @ $380.95 · Sale (S): 1,021 @ $779 · Option exercise (M): 1,021 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/award (A): 165 @ $0 · Grant/award (A): 1,929 (derivative) @ $0 | EDGAR |
| 2023-01-03 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 943 @ $39.76 | EDGAR |
| 2022-12-12 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 218 @ $380.95 · Sale (S): 218 @ $779 · Option exercise (M): 218 (derivative) @ $0 | EDGAR |
| 2022-09-30 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 913 @ $41.06 | EDGAR |
| 2022-09-12 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 1,279 @ $391.92 · Sale (S): 1,279 @ $705 · Option exercise (M): 1,279 @ $391.92 · Sale (S): 1,279 @ $686.99 · Option exercise (M): 609 @ $376.69 · Sale (S): 609 @ $741 · +3 more | EDGAR |
| 2022-06-30 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 903 @ $41.52 | EDGAR |
| 2022-06-24 | 4 | Cidara Therapeutics, Inc. (CDTX) | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2022-06-24 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 6,328 @ $0 | EDGAR |
| 2022-04-11 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 1,240 @ $380.95 · Sale (S): 1,240 @ $725 · Option exercise (M): 1,240 (derivative) @ $0 | EDGAR |
| 2022-04-01 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 964 @ $38.87 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1683607 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs